
Claims

1. Use of a crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide



for the manufacture of a medicament for the treatment of hypertension, pulmonary hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, portal hypertension, glomerulonephritis, diabetic complications, or chronic kidney disease (CKD);

wherein said crystalline form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

2. The use according to claim 1, wherein said medicament is for the treatment of hypertension.


3. The use according to claim 1, wherein said medicament is for the treatment of essential hypertension, resistant hypertension, pulmonary hypertension or pulmonary arterial hypertension.

4. The use according to claim 1, wherein said medicament is for the treatment of essential hypertension or resistant hypertension.

5. The use according to claim 1, wherein said medicament is for the treatment of resistant hypertension.

6 . The use according to claim 1, wherein said medicament is for the treatment of CKD of stages 1 to 4 as defined by the Kidney Disease Improving Global Outcomes (KDIGO) Guidelines; wherein said CKD is caused by essential hypertension.

7. Use of a crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide



for the manufacture of a medicament for the treatment of chronic kidney disease (CKD), diabetes, diabetic nephropathy, diabetic retinopathy, diabetic vasculopathy, chronic heart failure, or diastolic dysfunction;

wherein said crystalline form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

8. The use according to claim 7, wherein said medicament is for the treatment of diabetic nephropathy.

9. The use according to any one of claims 1 to 8, wherein said crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.8°, 9.9°, 11.7°, 17.8°, 18.6°, 20.0°, 21.5°, 22.8°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

10. The use according to any one of claims 1 to 8, wherein said crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamideessentially shows the X-ray powder diffraction pattern as depicted in Figure 1.

11. The use according to any one of claims 1 to 10, wherein said medicament is to be administered in form of a tablet consisting of a solid pharmaceutical composition comprising

- said crystalline form of the compound {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide in a total amount from 5 to 25% in weight based on the total weight of the pharmaceutical composition,
- microcrystalline cellulose in a total amount from 20 to 30% in weight based on the total weight of the pharmaceutical composition,
- lactose in a total amount from 40 to 65% in weight based on the total weight of the pharmaceutical composition, hydroxypropylcellulose in a total amount from 1 to 3% in weight based on the total weight of the pharmaceutical composition,
- croscarmellose sodium in a total amount from 2 to 8% in weight based on the total weight of the pharmaceutical composition, and
- magnesium stearate in a total amount from 0.2 to 2% in weight based on the total weight of the pharmaceutical composition;

wherein the total percent in weight of the solid pharmaceutical composition is 100.

12 . The use according to any one of claim 1 to 11, wherein said crystalline form of {5 (4 bromo-phenyl)-6 [2 (5 bromo-pyrimidin-2 yloxy)-ethoxy]-pyrimidin-4 yl}-sulfamide is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 50 mg per day of {5 (4 bromo-phenyl)-6 [2 (5 bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide.